|
KEY
PUBLICATION LIST
- Abenhaim
L, Moride Y, Brenot F et al. Appetite-suppressant
drugs and the risk of primary pulmonary hypertension. N
Engl J Med (1996) 335:609-16
- Abraham
DJ et al. Increased levels of endothelin-1 and
differential enthothelin type A and B receptor expression
in scleroderma-associated fibrotic lung disease. AM.
J. Pathol (1997) 151:831-841
- Alpert
MA et al. Cardiovascular manifestations of mixed
connective tissue disease in adults. Circulation
(1983): 68(6):1182-93
- Archer
S, Rich S. Primary pulmonary hypertension: a vascular biology
and translational research 'work in progress'. Circulation
(2000);102(22):2781-91
- Borg
GA. Psychophysical bases of perceived exertion. Med
Sci Sports Exerc (1982);14:377-381
- Brij
S, Peacock AJ. Pulmonary hypertension: its assessment and
treatment. Thorax (1999) 54(2):28-32
- Carratu
P et al. ET-1 induces mitogenesis in ovine airway
smooth muscle cells via ETA and ETB
receptors. Am. J. Physiol (1997) 272
:L1021-1024
- Channick
RN, Simonneau G, Sitbon O et al. Effects of the
dual endothelin-receptor antagonist bosentan in patients
with pulmonary hypertension: a randomized placebo controlled
study. Lancet (2000) 358:1119-1123
- Chen
SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S. Endothelin-receptor
antagonist bosentan prevents and reverses hypoxic pulmonary
hypertension in rats. J Appl Physiol (1995);79:2122-2131
- Clozel
M, Breu V, Gray GA et al. Pharmacological characterization
of bosentan, a new potent orally active nonpeptide endothelin
receptor antagonist. J. Pharmacol. Exp. Ther. (1994)
270:228-235
- D’Alonzo
GE, Barst RJ, Ayres SM et al. Survival in patients
with primary pulmonary hypertension: results from a national
prospective registry. Ann. Intern. Med. (1991)
115:343-349
- Ellahham
SH, Charlon V et al. Bosentan and the endothelin
system in congestive heart failure. Clin Cardiol
(2000);23:803-807
- Gaine
SP, Rubin LJ. Primary pulmonary hypertension. Lancet
(1998) 352:719-725
- Galiè
N, Grigioni F, Bacchi-Reggiani L, Ussia GP, Parlangeli R,
Catanzariti P, et al. Relation of endothelin-1
to survival in patients with primary pulmonary hypertension.
Eur J Clin Invest (1996); 26(1):273
- Galiè
N et al. Effects of beraprost sodium, an oral prostacyclin
analogue, in patients with pulmonary arterial hypertension:
A randomised, double-blind, placebo-controlled trial.
JACC (2002) 39(9);1496-502
- Giaid
A, Yanagisawa M, Langleben D et al. Expression
of endothelin-1 in the lungs of patients with pulmonary
hypertension. N. Engl. J. Med. (1993) 328:1732-1739
- Gibbs
JSR et al. Recommendations on the management of
pulmonary hypertension in clinical practice. Heart
(Sept 2001);86(1):i1-i13
- Ishikawa
S, Miyauchi T, Ueno H, et al. Influence of pulmonary
blood pressure and flow on endothelin-1 production in humans.
J Cardiovasc Pharmacol (1995); 26:429-433
- Kim
N, Rubin LJ. Endothelin in health and disease: Endothelin
receptor antagonism in the management of pulmonary artery
hypertension. J Cardiovasc Pharmacol Therapeut
(2002) 7(1):9-19
- Kleber
FX, Petersen S. The peripheral syndrome of heart failure:
the overlooked aspects. European Heart Journal
(1998) 19(L):L10-L14
- Koh
ET et al. Pulmonary hypertension in systemic sclerosis:
an analysis of 17 patients. Br J Rheumatol (1996);35:989-993
- Levin
ER. Endothelins. N Engl J Med (1995) 333:356-363
- Liu
J et al. Unique response of human arteries to endothelin
B receptor agonist and antagonist. Clin Sci (Lond)
(1996); 90(2): 91-96
- MacGregor
AJ et al. Pulmonary hypertension in systemic sclerosis:
risk factors for progression and consequences for survival.
Rheumatology (2001); 40;453-59
- McCulloch
KM. et al. EnothelinB receptor-mediated contraction
in human pulmonary risistance arteries. Br. J. Pharmacol.,
(1996) 119:1125-1130
- Miyamoto
S et al. Clinical correlates and prognostic significance
of six-minute walk test in patients with primary pulmonary
hypertension: Comparison with cardiopulmonary hypertension.
Am J Resp and Crit Care Med (2000);161:487-492
- Nagaya
N et al. Oral beraprost sodium improves exercise
capacity and ventilatory efficiency in patients with primary
or thromboembolic pulmonary hypertension. Heart
(2002) 87:340-345
- Olschewski
H et al. Inhaled iloprost for severe pulmonary
arterial hypertension. N Engl J Med (2002):347:322-329
- Park
S-H, Saleh D, Giaid A, Michel RP. Increased enothelin-1
in bleomycin-induced pulmonary fibrosis and the effect of
an endothelin receptor antagonist. Am. J. Resp. Crit.
Care Med. (1997) 156:600-608
- Rich
S, Dantzker DR, Ayres SM et al. Primary pulmonary
hypertension: A national prospective study. Ann Intern
Med (1987) 107:216-23
- Rich
S (Ed). Primary pulmonary hypertension: Executive summary
from the WHO symposium, Evian, France 6-10 Sept 1998
- Rossi
GP et al. Measurement of endothelin: clinical and
research use. Ann Clin Biochem (2000) ;37:608-626
- Roux
S, Brue V, Ertel SI, Clozel M. Endothelin antagonism with
bosentan: a review of potential applications. J Mol
Med (1999);77:364-376
- Rubin
LJ. Primary pulmonary hypertension. N. Engl. J. Med
(1997) 336:111-117
- Rubin
LJ, Badesch DB, Barst RJ et al. Bosentan therapy
for pulmonary arterial hypertension. N. Engl. J. Med
(2002) 346:896-903
- Saleh
D, Furukawa K, Tsao MS, Maghazachi A, Corrin B, Yanagisawa
M, et al. Elevated expression of endothelin-1 and
endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis:
possible involvement of proinflammatory cytokines. Am
J Respir Cell Mol Biol (1997); 16:187-193
- Shi-wen
X et al. Fibroblast matrix gene expression and
connective tissue remodelling: J Invest Dermatol
(2001); 116:417-25
- Tilton
RG, Brock TA, Dixon RAF. Therapeutic potential of endothelin
receptor antagonists and nitric oxide donors in pulmonary
hypertension. Expert Opin Investig Drugs (2001);10(7):1291-1308
- Veyssier-Belot
C, Cacoub P. Role of endothelial and smooth muscle cells
in the physiopathology and treatment management of pulmonary
hypertension. Cardiovasc. Res (1999) 44:274-282
- Wilkins
MR, Wharton J. Progress in, and future prospects for, the
treatment of primary pulmonary hypertension. Heart
(2001) 86;603-604
- Yanagisawa
M et al. A novel potent vasoconstrictor peptide
produced by vascular endothelial cells. Nature
(March 1988);332:411-415
- Yoshida
et al. Endothelin-1 augments pressor response to
angiotension II infusion in rats. Hypertension
(1992); 20:292-97
- Zouki
C et al. Enothelin-1 enhances neutrophil adhesion
to human coronary artery endothelial cells: role of ETA
receptors and platelet-activating factor. Br J Pharmacol
(1999); 127:969-79
|
|
